Results from plasmaMATCH trial cohort E: A phase II trial of olaparib and ceralasertib in patients with triple-negative advanced breast cancer (CRUK/15/010).

被引：0
|
作者：
Ring, Alistair E.
Moretti, Laura
Afshari-Mehr, Angelica
Wardley, Andrew M.
Kilburn, Lucy
Gurel, Bora
MacPherson, Iain R.
Baird, Richard D.
Martin, Sue
Pearson, Alex
Roylance, Rebecca
Winter, Matthew
Dunne, Kathryn
Copson, Ellen
Hickish, Tamas
Stephens, Peter
Burcombe, Russell J.
Randle, Katrina
Bliss, Judith
Turner, Nicholas C.
机构：
[1] Royal Marsden NHS Fdn Trust, Surrey, England
[2] Inst Canc Res, Clin Trials & Stat Unit, London, England
[3] Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, London, England
[4] Outreach Res & Innovat Grp, Manchester, England
[5] Inst Canc Res, London, England
[6] Beatson West Scotland Canc Ctr, Glasgow, Scotland
[7] Canc Res UK, Cambridge Ctr, Cambridge, England
[8] Univ Coll London Hosp NHS Fdn Trust, London, England
[9] Univ Coll London Hosp, Biomed Res Ctr, NIHR, London, England
[10] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, England
[11] Royal Marsden Hosp, Ralph Lauren Ctr Breast Canc Res, London, England
[12] Univ Southampton, Southampton, England
[13] Royal Bournemouth Hosp, Bournemouth, England
[14] Poole Gen Hosp, Bournemouth, England
[15] Royal Devon & Exeter Hosp, Exeter, England
[16] Maidstone & Tunbridge Wells NHS Trust, Maidstone, Kent, England
[17] Independent Canc Patients Voice, London, England
[18] Royal Marsden Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1024
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)
    Ring, Alistair
    Kilburn, Lucy S.
    Pearson, Alex
    Moretti, Laura
    Afshari-Mehr, Angelica
    Wardley, Andrew M.
    Gurel, Bora
    Macpherson, Iain R.
    Riisnaes, Ruth
    Baird, Richard D.
    Martin, Sue
    Roylance, Rebecca
    Johnson, Hannah
    Ferreira, Ana
    Winter, Matthew C.
    Dunne, Kathryn
    Copson, Ellen
    Hickish, Tamas
    Burcombe, Russell
    Randle, Kat
    Serra, Violeta
    Llop-Guevara, Alba
    Bliss, Judith M.
    Turner, Nicolas C.
    CLINICAL CANCER RESEARCH, 2023, 29 (23) : 4751 - 4759
  • [2] Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial
    Loap, Pierre
    Loirat, Delphine
    Berger, Frederique
    Rodrigues, Manuel
    Bazire, Louis
    Pierga, Jean-Yves
    Vincent-Salomon, Anne
    Laki, Fatima
    Boudali, Latifa
    Raizonville, Laurence
    Mosseri, Veronique
    Jochem, Anne
    Eeckhoutte, Alexandre
    Diallo, Mamadou
    Stern, Marc-Henri
    Fourquet, Alain
    Kirova, Youlia
    JAMA ONCOLOGY, 2022, 8 (12) : 1802 - 1808
  • [3] Results from the plasmaMATCH trial: A multiple parallel cohort, multi-centre clinical trial of circulating tumour DNA testing to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010)
    Turner, Nicholas
    Kingston, Belinda
    Kilburn, Lucy
    Kernaghan, Sarah
    Wardley, Andrew M.
    Macpherson, Iain
    Baird, Richard D.
    Roylance, Rebecca
    Stephens, Peter
    Oikonomidou, Olga
    Braybrooke, Jeremy P.
    Tuthill, Mark
    Abraham, Jacinta
    Winter, Matthew C.
    Bye, Hannah
    Hubank, Michael
    Snowdon, Claire
    Rea, Daniel
    Cameron, David
    Shaaban, Abeer
    Randle, Katrina
    Wilkinson, Katie
    Moretti, Laura
    Bliss, Judith M.
    Ring, Alistair
    CANCER RESEARCH, 2020, 80 (04)
  • [4] The plasmaMATCH trial: A multiple parallel cohort, open-label, multi-centre phase II clinical trial of ctDNA screening to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010)
    Turner, Nicholas
    Bye, Hannah
    Kernaghan, Sarah
    Proszek, Paula
    Fribbens, Charlotte
    Moretti, Laura
    Morden, James
    Snowdon, Claire
    Macpherson, Iain
    Wardley, Andrew
    Roylance, Rebecca
    Baird, Richard
    Bliss, Judith
    Ring, Alistair
    CANCER RESEARCH, 2018, 78 (04)
  • [5] Results from plasmaMATCH trial treatment cohort C: A phase II trial of capivasertib plus fulvestrant in ER positive breast cancer patients with an AKT1 mutation identified via ctDNA screening (CRUK/15/010)
    Roylance, Rebecca
    Kilburn, Lucy
    Kernaghan, Sarah
    Wardley, Andrew M.
    Macpherson, Iain
    Baird, Richard D.
    Stephens, Peter
    Oikonomidou, Olga
    Braybrooke, Jeremy P.
    Tuthill, Mark
    Abraham, Jacinta
    Winter, Matthew C.
    Kingston, Belinda
    Wilkinson, Katie
    Ring, Alistair
    Bliss, Judith M.
    Turner, Nicholas
    CANCER RESEARCH, 2020, 80 (04)
  • [6] Results from plasmaMATCH trial treatment cohort D: A phase II trial of capivasertib in patients with an AKT activation basket mutation identified via ctDNA testing or tumour sequencing (CRUK/15/010)
    Baird, Richard D.
    Kilburn, Lucy
    Kernaghan, Sarah
    Wardley, Andrew M.
    Macpherson, Iain
    Roylance, Rebecca
    Stephens, Peter
    Oikonomidou, Olga
    Braybrooke, Jeremy P.
    Tuthill, Mark
    Abraham, Jacinta
    Winter, Matthew C.
    Kingston, Belinda
    Wilkinson, Katie
    Turner, Nicholas
    Ring, Alistair
    Bliss, Judith M.
    CANCER RESEARCH, 2020, 80 (04)
  • [7] Results from plasmaMATCH trial treatment cohort B: A phase II trial of neratinib plus fulvestrant in ER positive breast cancer or neratinib alone in ER negative breast cancer in patients with a HER2 mutation identified via ctDNA screening (CRUK/15/010)
    Wardley, Andrew M.
    Kilburn, Lucy
    Kernaghan, Sarah
    Macpherson, Iain
    Baird, Richard D.
    Roylance, Rebecca
    Stephens, Peter
    Oikonomidou, Olga
    Braybrooke, Jeremy P.
    Tuthill, Mark
    Abraham, Jacinta
    Winter, Matthew C.
    Kingston, Belinda
    Wilkinson, Katie
    Bliss, Judith M.
    Ring, Alistair
    Turner, Nicholas
    CANCER RESEARCH, 2020, 80 (04)
  • [8] Results from plasmaMATCH trial treatment cohort A: A phase II trial of extended-dose fulvestrant in patients with an ESR1 mutation identified via ctDNA screening (CRUK/15/010)
    Macpherson, Iain
    Kilburn, Lucy
    Kernaghan, Sarah
    Wardley, Andrew M.
    Baird, Richard D.
    Roylance, Rebecca
    Stephens, Peter
    Oikonomidou, Olga
    Braybrooke, Jeremy P.
    Tuthill, Mark
    Abraham, Jacinta
    Winter, Matthew C.
    Kingston, Belinda
    Wilkinson, Katie
    Ring, Alistair
    Bliss, Judith M.
    Turner, Nicholas
    CANCER RESEARCH, 2020, 80 (04)
  • [9] Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer
    Batalini, Felipe
    Xiong, Niya
    Tayob, Nabihah
    Polak, Madeline
    Eismann, Julia
    Cantley, Lewis C.
    Shapiro, Geoffrey, I
    Adalsteinsson, Viktor
    Winer, Eric P.
    Konstantinopoulos, Panagiotis A.
    D'Andrea, Alan
    Swisher, Elizabeth M.
    Matulonis, Ursula A.
    Wulf, Gerburg M.
    Mayer, Erica L.
    CLINICAL CANCER RESEARCH, 2022, 28 (08) : 1493 - 1499
  • [10] Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial
    Mengru Cao
    Hailing Lu
    Shi Yan
    Hui Pang
    Lichun Sun
    Chunhong Li
    Xuesong Chen
    Wei Liu
    Jing Hu
    Jian Huang
    Ying Xing
    Ningzhi Zhang
    Yingqi Chen
    Ting He
    Danni Zhao
    Yuanyuan Sun
    Lin Zhao
    Xiaomeng Liu
    Li Cai
    BMC Cancer, 23
12345